8-K: Seelos Therapeutics Receives FDA Agreement on Phase III Endpoints for SLS-002 Depression Treatment

Seelos Therapeutics has secured FDA agreement on modified endpoints for its Phase III trial of SLS-002 for major depressive disorder, paving the way for further development.

Summary

• Seelos Therapeutics announced that the FDA has agreed to modifications of the primary and secondary endpoints for the Phase III trial of SLS-002, a treatment for Major Depressive Disorder (MDD) at imminent risk of suicide.
• The primary endpoint for the Phase III trial will now be the change from baseline in the Montgomery-sberg Depression Rating Scale (MADRS) total score at Day 16, instead of the 24-hour timepoint used in the Phase II study.
• The key secondary endpoint will be the change from baseline at 24 hours on the suicidality scale.
• The company plans to continue partnership discussions and move forward with a Phase III trial for SLS-002.
• Phase II data showed clinically significant treatment differences from placebo on both the Day 16 MADRS (p-value: 0.012) and the 24-hour Sheehan-Suicidality Tracking Scale (S-STS) (p-value: 0.008).
• There were 49,449 suicides in the U.S. in 2022, and the medical community lacks an FDA-approved therapeutic to treat the symptoms of suicidality.
• In 2020, suicides and non-fatal self-harm cost the U.S. over $500 billion in medical and work-loss costs, value of statistical life, and quality of life costs.
• In 2019, there were more than 1,000,000 visits to emergency rooms for suicide attempts in the U.S.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA agreement on endpoints and promising Phase II data. However, there are still risks associated with clinical trials and funding.

Positives

• The FDA agreement on modified endpoints provides clarity and confidence for the Phase III development of SLS-002.
• The Phase II data showed statistically significant results, suggesting the potential efficacy of SLS-002.
• The company is actively pursuing a partnership to support the development of SLS-002.
• SLS-002 addresses a significant unmet need for a therapy to treat suicidality, where current treatments are often slow or have side effects.
• The company is participating in the DOD adaptive platform trial for PTSD, expanding the potential applications of their research.

Negatives

• The document highlights the lack of FDA-approved therapeutics for suicidality, indicating the challenges in this area.
• The high cost of suicides and non-fatal self-harm to the U.S. economy underscores the severity of the problem.

Risks

• There is a risk that the Phase III trial may not replicate the positive results seen in Phase II.
• The company may not be able to secure a partnership to support the development of SLS-002.
• There is a risk that the clinical study results may not meet all endpoints or support regulatory approval.
• The company faces risks related to raising capital to fund its development plans and ongoing operations.
• The company's current stock price is a risk factor.

Future Outlook

Seelos expects to proceed to Phase III with SLS-002 in adults with Major Depressive Disorder at imminent risk of suicide and is also participating in the U.S. Department of Defenses (DOD) adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD).

Management Comments

• Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, stated that they are very excited about the potential that SLS-002 has to address the unmet need of acute suicidality.
• Tim Whitaker, M.D., Chief Medical Officer of Seelos, thanked the FDA for the collaborative discussion and looks forward to future discussions on the modifications for the Phase III protocol.

Industry Context

The announcement is significant as it addresses a critical unmet need in the treatment of suicidality, a major public health concern. The lack of FDA-approved treatments in this area highlights the importance of Seelos' work. The use of ketamine, while experimental, is gaining attention for its potential rapid effects on depression and suicidality.

Comparison to Industry Standards

• The document mentions that traditional anti-depressants are often slow to take effect and can sometimes increase suicidal thoughts, highlighting a key differentiator for SLS-002.
• The use of intranasal ketamine is a novel approach compared to traditional oral antidepressants, potentially offering a faster onset of action.
• The document references the high number of emergency room visits for suicide attempts, indicating a significant market opportunity for effective treatments like SLS-002.
• The company's participation in the DOD adaptive platform trial for PTSD is a positive sign, as it demonstrates the potential for broader applications of their research.

Stakeholder Impact

• Shareholders will likely view the FDA agreement and positive Phase II data favorably.
• Patients with MDD and at risk of suicide may benefit from the development of SLS-002.
• The medical community may see this as a step forward in addressing the unmet need for effective treatments for suicidality.

Next Steps

• Seelos plans to continue its previously announced potential partnership discussions.
• The company expects to proceed to Phase III with SLS-002 in adults with Major Depressive Disorder at imminent risk of suicide.
• Seelos will participate in the U.S. Department of Defenses (DOD) adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD).

Key Dates

Keywords

SLS-002, Major Depressive Disorder, Suicidality, FDA, Phase III Trial, Montgomery-sberg Depression Rating Scale, MADRS, Sheehan-Suicidality Tracking Scale, S-STS, Ketamine, Post-Traumatic Stress Disorder, PTSD, Clinical Trial, Biopharmaceutical